In July 2007, the Tennessee General Assembly established the Tennessee Alzheimer’s Disease Task Force to assess the current and future impact of Alzheimer’s disease in Tennessee, examine services and resources, and draft a state strategy to respond to Alzheimer’s within the state. The Task Force included representatives from long-term care organizations, adult day providers, physician groups, community organizations, state agencies, caregivers, individuals living with the disease and state legislators. In February 2009, the Task Force published the Tennessee Alzheimer’s Disease Task Force Final Report.

In May of 2019, the Tennessee General Assembly enacted Senate Bill 28 (Public Chapter No. 364) establishing the Tennessee Alzheimer’s Disease Advisory Council. In January 2020, the Advisory Council published the updated Alzheimer’s and Related Dementia State Plan.

Improve Access to Biomarker Testing 

With the historic Food and Drug Administration (FDA) approval of treatments that slow the progression of Alzheimer’s in the early stages, early detection and diagnosis are even more critical to ensure individuals receive the most benefit at the earliest point possible. Biomarkers offer one of the most promising paths to improve dementia detection, diagnosis and treatment. Yet these critical tests remain out of reach for many as insurance coverage is failing to keep pace with innovations and advancements in treatments. The Alzheimer’s Association is urging state lawmakers to expand insurance coverage of comprehensive biomarker testing. Without this legislation, dementia diagnoses may take up to two years, increasing the long-term costs to the individual, family and the state.